



PTO/SB/08 (2/92)  
Sheet 1 of 1

|   |                 |   |                                    |   |                                 |   |
|---|-----------------|---|------------------------------------|---|---------------------------------|---|
| <b>Form PTO-1449</b>  |                 | <b>Attorney's Docket No.</b><br>39750-0065A   |                                    | <b>Application Serial No.</b><br>09/272,835 |                                 |   |
| <b>INFORMATION DISCLOSURE STATEMENT</b>   |                 | <b>Applicant(s)</b><br>Frederic J. de SAUVAGE, et al.   |                                    |   |                                 |   |
| <b>(use several sheets if necessary)</b>  |                 | <b>Filing Date:</b><br>March 19, 1999   |                                    | <b>Group Art Unit:</b><br>1647              |                                 |   |
| <b>U.S. PATENT DOCUMENTS</b>  |                 |   |                                    |   |                                 |   |
| <b>Examiner Initials</b>  | <b>Ref. No.</b> | <b>Date</b>   | <b>Document No.</b>                | <b>Name</b>                                 | <b>Class</b><br><b>Subclass</b> | <b>Filing Date</b><br><b>(if appropriate)</b> |
|   |                 |   |                                    |   |                                 |   |
| <b>FOREIGN PATENT DOCUMENTS</b>   |                 |   |                                    |   |                                 |   |
| <b>Examiner Initials</b>  | <b>Ref. No.</b> | <b>Date</b>   | <b>Document No.</b>                | <b>Name</b>                                 | <b>Class</b><br><b>Subclass</b> | <b>Translation</b><br><b>YES</b> <b>NO</b>    |
|   |                 |   |                                    |   |                                 |   |
| <b>OTHER DOCUMENTS</b><br><i>(including author, title, date, pertinent pages, etc.)</i>   |                 |   |                                    |   |                                 |   |
| <b>Examiner Initials</b>  | <b>Ref. No.</b> | <b>Title</b>  |                                    |   |                                 |   |
|   | 1               | Andres et al., <i>Development</i> 128(10):3685-3695 (2001)<br>Multiple effects of artemin on sympathetic neurone generation, survival and growth  |                                    |   |                                 |   |
|   | 2               | Baloh et al., <i>Neuron</i> 21: 1291-1302 (1998)<br>Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex |                                    |   |                                 |   |
|   | 3               | Esteve, "Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer," <i>The Oncologist</i> 9(Suppl 3):4-9 (2004), page 6, column 1, lines 8-16).                         |                                    |   |                                 |   |
|   | 4               | Negro et al., <i>Recent Prog Horm Res.</i> 59:1-12 (2004)<br>Essential roles of Her2/erbB2 in cardiac development and function  |                                    |   |                                 |   |
|   | 5               | Rosická et al., <i>Physiological Research</i> 51:435-441 (2002)<br>Ghrelin - a New Endogenous Growth Hormone Secretagogue   |                                    |   |                                 |   |
|   | 6               | Smith et al., <i>Best Pract Res Clin endocrinol Metab.</i> 18(3):333-347 (2004)<br>Growth hormone secretagogues: prospects and potential pitfalls   |                                    |   |                                 |   |
|   | 7               | Thilenius et al., <i>Eur. J. Immunol.</i> 27(5):1108-1114 (1997)<br>Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants   |                                    |   |                                 |   |
| <b>EXAMINER:</b><br>  |                 |   | <b>DATE CONSIDERED:</b><br>3/24/05 |   |                                 |   |
| <b>EXAMINER:</b> Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.   |                 |   |                                    |   |                                 |   |
| *If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). |                 |   |                                    |   |                                 |   |